Title of Invention	3,6-DIHYDRO-2-OXO-6H-1,3,4-THIADIAZINES DERIVATIVES
Abstract	Compounds of the formula I, in which R1, R2, Q and B have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular of Met Kinase and can be employed, inter alia, for treatment of tumours.

Full Text

3,6-Dihydro-2-oxo-6H-1,3,4-thiadiazine derivatives BACKGROUND OF THE INVENTION The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments. The present invention relates to compounds and to the use of compounds in which the inhibition, regulation and/or modulation of signal transduction by kinases, in particular tyrosine kinases and/or serine/threonine kinases, plays a role, furthermore to pharmaceutical compositions which comprise these compounds, and to the use of the compounds for the treatment of kinase-induced diseases. In particular, the present invention relates to compounds and to the use of compounds in which the inhibition, regulation and/or modulation of signal transduction by Met kinase plays a role. One of the principal mechanisms by which cellular regulation is effected is through the transduction of extracellular signals across the membrane that in turn modulate biochemical pathways within the cell. Protein phosphoryl- ation represents one course by which intracellular signals are propagated from molecule to molecule resulting finally in a cellular response. These signal transduction cascades are highly regulated and often overlap, as is evident from the existence of many protein kinases as well as phosphata- ses. Phosphorylation of proteins occurs predominantly at serine, threonine or tyrosine residues, and protein kinases have therefore been classified by their specificity of phosphorylation site, i.e. serine/threonine kinases and tyrosine kinases. Since phosphorylation is such a ubiquitous process within cells and since cellular phenotypes are largely influenced by the activity of these pathways, it is currently believed that a number of disease states and/or diseases are attributable to either aberrant activation or functional mutations in the molecular components of kinase cascades. Consequently, considerable attention has been devoted to the characteri- sation of these proteins and compounds that are able to modulate their activity (for a review see: Weinstein-Oppenheimer et al. Pharma. &. Therap., 2000, 88, 229-279). The role of the receptor tyrosine kinase Met in human oncogenesis and the possibility of inhibition of HGF (hepatocyte growth factor)dependent Met activation are described by S. Berthou et al. in Oncogene, Vol. 23, No. 31, pages 5387-5393 (2004). The inhibitor SU11274 described therein, a pyrrole-indoline compound, is potentially suitable for combating cancer. Another Met kinase inhibitor for cancer therapy is described by J.G. Christensen et al. in Cancer Res. 2003, 63(21), 7345-55. A further tyrosine kinase inhibitor for combating cancer is reported by H. Hov et al. in Clinical Cancer Research Vol. 10, 6686-6694 (2004). The compound PHA-665752, an indole derivative, is directed against the HGF receptor c-Met. It is furthermore reported therein that HGF and Met make a considerable contribution to the malignant process of various forms of cancer, such as, for example, multiple myeloma. The synthesis of small compounds which specifically inhibit, regulate and/or modulate signal transduction by tyrosine kinases and/or serine/- threonine kinases, in particular Met kinase, is therefore desirable and an aim of the present invention. It has been found that the compounds according to the invention and salts thereof have very valuable pharmacological properties while being well tol- erated. The present invention specifically relates to compounds of the formula I which inhibit, regulate and/or modulate signal transduction by Met kinase, to compositions which comprise these compounds, and to processes for the use thereof for the treatment of Met kinase-induced diseases and com- plaints, such as angiogenesis, cancer, tumour formation, growth and propagation, arteriosclerosis, ocular diseases, such as age-induced macular degeneration, choroidal neovascularisation and diabetic retino- pathy, inflammatory diseases, arthritis, thrombosis, fibrosis, glomerulo- nephritis, neurodegeneration, psoriasis, restenosis, wound healing, trans- plant rejection, metabolic diseases and diseases of the immune system, also autoimmune diseases, cirrhosis, diabetes and diseases of the blood vessels, also instability and permeability and the like in mammals. Solid tumours, in particular fast-growing tumours, can be treated with Met kinase inhibitors. These solid tumours include monocytic leukaemia, brain, urogenital, lymphatic system, stomach, laryngeal and lung carcinoma, in- cluding lung adenocarcinoma and small-cell lung carcinoma. The present invention is directed to processes for the regulation, modula- tion or inhibition of Met kinase for the prevention and/or treatment of dis- eases in connection with unregulated or disturbed Met kinase activity. In particular, the compounds of the formula I can also be employed in the treatment of certain forms of cancer. The compounds of the formula I can furthermore be used to provide additive or synergistic effects in certain existing cancer chemotherapies, and/or can be used to restore the efficacy of certain existing cancer chemotherapies and radiotherapies. The compounds of the formula I can furthermore be used for the isolation and investigation of the activity or expression of Met kinase. In addition, they are particularly suitable for use in diagnostic methods for diseases in connection with unregulated or disturbed Met kinase activity. It can be shown that the compounds according to the invention have an antiproliferative action in vivo in a xenotransplant tumour model. The com- pounds according to the invention are administered to a patient having a hyperproliferative disease, for example to inhibit tumour growth, to reduce inflammation associated with a lymphoproliferative disease, to inhibit trans- plant rejection or neurological damage due to tissue repair, etc. The pre- sent compounds are suitable for prophylactic or therapeutic purposes. As used herein, the term "treatment" is used to refer to both prevention of dis- eases and treatment of pre-existing conditions. The prevention of prolif- eration is achieved by administration of the compounds according to the invention prior to the development of overt disease, for example to prevent the growth of tumours, prevent metastatic growth, diminish restenosis as- sociated with cardiovascular surgery, etc. Alternatively, the compounds are used for the treatment of ongoing diseases by stabilising or improving the clinical symptoms of the patient. The host or patient can belong to any mammalian species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of in- terest for experimental investigations, providing a model for treatment of human disease. The susceptibility of a particular cell to treatment with the compounds according to the invention can be determined by in vitro tests. Typically, a culture of the cell is combined with a compound according to the invention at various concentrations for a periodine of time which is sufficient to allow the active agents to induce cell death or to inhibit migration, usually between about one hour and one week. In vitro testing can be carried out using cultivated cells from a biopsy sample. The viable cells remaining after the treatment are then counted. The dose varies depending on the specific compound used, the specific disease, the patient status, etc. A therapeutic dose is typically sufficient considerably to reduce the undesired cell population in the target tissue while the viability of the patient is maintained. The treatment is generally continued until a considerable reduction has occurred, for example an at least about 50% reduction in the cell burden, and may be continued until essentially no more undesired cells are detected in the body. For identification of a signal transduction pathway and for detection of interactions between various signal transduction pathways, various scien- tists have developed suitable models or model systems, for example cell culture models (for example Khwaja et al., EMBO, 1997, 16, 2783-93) and models of transgenic animals (for example White et al., Oncogene, 2001, 20, 7064-7072). For the determination of certain stages in the signal trans- duction cascade, interacting compounds can be utilised in order to modu- late the signal (for example Stephens et al., Biochemical J., 2000, 351, 95- 105). The compounds according to the invention can also be used as re- agents for testing kinase-dependent signal transduction pathways in ani- mals and/or cell culture models or in the clinical diseases mentioned in this application. Measurement of the kinase activity is a technique which is well known to the person skilled in the art. Generic test systems for the determination of the kinase activity using substrates, for example histone (for example Alessi et al., FEBS Lett. 1996, 399, 3, pages 333-338) or the basic myelin protein, are described in the literature (for example Campos-Gonzalez, R. and Glenney, Jr., J.R. 1992, J. Biol. Chem. 267, page 14535). For the identification of kinase inhibitors, various assay systems are avail- able. In scintillation proximity assay (Sorg et al., J. of. Biomolecular Screening, 2:002, 7, 11-19) and flashplate assay, the radioactive phos- phorylation of a protein or peptide as substrate with ATP is measured. In the presence of an inhibitory compound, a decreased radioactive signal, or none at all, is detectable. Furthermore, homogeneous time-resolved fluo- rescence resonance energy transfer (HTR-FRET) and fluorescence polari- sation (FP) technologies are suitable as assay methods (Sills et al., J. of Biomolecular Screening, 2002, 191-214). Other non-radioactive ELISA assay methods use specific phospho-anti- bodies (phospho-ABs). The phospho-AB binds only the phosphorylated substrate. This binding can be detected by chemiluminescence using a second peroxidase-conjugated anti-sheep antibody (Ross et al., 2002, Biochem. J.). There are many diseases associated with deregulation of cellular prolifera- tion and cell death (apoptosis). The conditions of interest include, but are not limited to, the following. The compounds according to the invention are suitable for the treatment of various conditions where there is proliferation and/or migration of smooth muscle cells and/or inflammatory cells into the intimal layer of a vessel, resulting in restricted blood flow through that ves- sel, for example in the case of neointimal occlusive lesions. Occlusive graft vascular diseases of interest include atherosclerosis, coronary vascular disease after grafting, vein graft stenosis, peri-anastomatic prosthetic restenosis, restenosis after angioplasty or stent placement, and the like. PRIOR ART Other thiadiazinones are described in WO 03/037349. 4,5-dihydropyrazoles for combating cancer are described in WO 03/079973 A2. Quinoline derivatives are disclosed as Met kinase inhibitors in EP 1 411 046 A1. Pyrrole-indoline derivatives are known as Met kinase inhibitors from WO 02/096361 A2. SUMMARY OF THE INVENTION The invention relates to compounds of the formula I in which R1 denotes H, A, Hal, OH, OA, SH, SA, SOA, SO2A, NO2, NH2, NHA, NAA', SO2NH2, SO2NHA, SO2NAA', CONH2, CONHA, CONAA', NACOA', NASO2A', COOH, COOA or CN, R2 denotes H, A, Hal, SO2NH2, SO2NHA, SO2NAA', CONH2, CONHA, CONAA', NACOA', NASO2A', COOH, COOA or CN, R1 and R2 together also denote methylenedioxy, B is absent, denotes NHCOCONH(CH2)nR3, NHCOCONA(CH2)nR3, NHCOCOO(CH2)nR3, OCONH(CH2)nR3, OCONA(CH2)nR3, NHCONH(CH2)nR3, NACONH(CH2)nR3, N(CH2)nR3, CONH(CH2)nR3, SO2NH(CH2)nR3, SO2NA(CH2)nR3, NHSO2(CH2)nR3 or NASO2(CH2)nR3, Q is absent or denotes alkylene having 1-4 C atoms, R3 denotes R1, Het or alkyl having 1-6 C atoms or cycloalkyl having 3-8 C atoms, each of which is unsubstituted or mono-, di-, tri- or tetrasubstituted by R4, R4 denotes A, Hal, OH, OA, SH, SA, SOA, SO2A, NO2, NH2, NHA, NAA', SO2NH2, SO2NHA, SO2NAA', CONH2, CONHA, CONAA', NACOA', NASO2A', COOH, COOA or CN, Het denotes a mono- or bicyclic saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by R4, CHO, COA, =S, =NH, =NA and/or =0 (carbonyl oxygen), A, A' each, independently of one another, denote unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, Cl and/or Br, cycloalkyl having 3-8 C atoms or cycloalkylalkylene having 4-10 C atoms, Hal denotes F, Cl, Br or I, n denotes 0, 1, 2 or 3, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and sol- vates of these compounds. The term solvates of the compounds is taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force, solvates are, for example, mono- or dihydrates or alkoxides. The term pharmaceutically usable derivatives is taken to mean, for exam- ple, the salts of the compounds according to the invention and also so- called prodrug compounds. The term prodrug derivatives is taken to mean compounds of the formula I which have been modified by means of, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the effective compounds according to the invention. These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 115,61-67(1995). The expression "effective amount" denotes the amount of a medicament or of a pharmaceutical active ingredient which causes in a tissue, system, animal or human a biological or medical response which is sought or de- sired, for example, by a researcher or physician. In addition, the expression "therapeutically effective amount" denotes an amount which, compared with a corresponding subject who has not re- ceived this amount, has the following consequence: improved treatment, healing, prevention or elimination of a disease, syn- drome, condition, complaint, disorder or side-effects or also the reduction in the advance of a disease, complaint or disorder. The expression "therapeutically effective amount" also encompasses the amounts which are effective for increasing normal physiological function. The invention also relates to the use of mixtures of the compounds of the formula I, for example mixtures of two diastereomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000. These are particularly preferably mixtures of stereoisomeric compounds. The invention relates to the compounds of the formula I and salts thereof and to a process for the preparation of compounds of the formula I accord- ing to Claims 1-11 and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, characterised in that a) a compound of the formula la in which B denotes NH2, and R1, R2 and Q have the meanings indicated in Claim 1, is converted into a compound of the formula I in which B denotes NHCONH(CH2)nR3, by reacting a compound of the formula la with a coupling reagent selected from the group a) isoproylidene chloroformate, b) p-nitrophenyl chloroformate, c) diphosgene, d) triphosgene, and a compound of the formula II H2N(CH2)nR3 II in which n and R3 have the meanings indicated in Claim 1, or b) a compound of the formula la is acylated or sulfonylated and/or a base or acid of the formula I is converted into one of its salts. Above and below, the radicals R1, R2, Q and B have the meanings indi- cated for the formula I, unless expressly stated otherwise. A or A' denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1- ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1-or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2- methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, furthermore preferably, for example, trifluoromethyl. A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoro- ethyl. cycloalkyl preferably denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclo- hexyl or cycloheptyl. Cycloalkylalkylene preferably denotes cyclopropylmethyl, cyclobutylmethyl, cylopentylmethyl, cyclohexylmethyl or cycloheptylmethyl. Het preferably denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be mono- or disubstituted by A and/or =0 (carbonyl oxygen). Het particularly preferably denotes piperidinyl, pyrrolidinyl, morpholin-4-yl, piperazinyl, 1,3-oxazolidin-3-yl or imidazolidinyl, where the radicals may also be mono- or disubstituted by A. R1 preferably denotes Hal, OH or CN, in particular Cl or OH, very particularly preferably 4-CI. R2 preferably denotes H or Hal, particularly preferably H. B preferably denotes NHCOCONH(CH2)nR3, NHCOCOO(CH2)nR3, NHCONH(CH2)nR3 or NHSO2(CH2)nR3. The radical B is preferably in the meta-position to Q. Q preferably denotes CH2. R3 preferably denotes H, Het or alkyl having 1-6 C atoms or cycloalkyl having 3-8 C atoms, each of which is unsubstituted or mono-, di-, tri- or tetrasubstituted by R4. R3 particularly preferably denotes H, 2-hydroxyethyl, 2-hydroxypropyl, pyrrolidinyl, N-methylpyrrolidinyl, morpholin-4-yl, 3-(N,N-diethylamino)- propyl, 3-(N,N-dimethylamino)propyl, methyl, ethyl or propyl. R4 preferably denotes OH, amino, methylamino, dimethylamino, ethyl- amino or diethylamino. Hal preferably denotes F, Cl or Br, but also I, particularly preferably F or Cl. Throughout the invention, all radicals which occur more than once may be identical or different, i.e. are independent of one another. The compounds of the formula I may have one or more chiral centres and can therefore occur in various stereoisomeric forms. The formula I encom- passes all these forms. Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds may be expressed by the following sub-formulae la to li, which conform to the for- mula I and in which the radicals not designated in greater detail have the meaning indicated for the formula I, but in which in la R1 denotes Hal, OH or CN; in Ib R2 denotes H or Hal; in Ic B denotes NHCOCONH(CH2)nR3, NHCOCOO(CH2)nR3, NHCONH(CH2)nR3 or NHSO2(CH2)nR3; in Id Q denotes CH2; in le R3 denotes H, Het or alkyl having 1-6 C atoms or cycloalkyl having 3-8 C atoms, each of which is unsubstituted or mono-, di-, tri- or tetrasubstituted by R4; in If R4 denotes OH, NH2, NHA or NAA'; in Ig A, A' each, independently of one another, denote unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F and/or chlorine; in Ih Het denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A; in li R1 denotes Hal, OH or CN, R2 denotes H or Hal, B denotes NHCOCONH(CH2)nR3, NHCOCOO(CH2)nR3, NHCONH(CH2)nR3 or NHSO2(CH2)nR3, Q denotes CH2, R3 denotes H, Het or alkyl having 1-6 C atoms or cycloalkyl having 3-8 C atoms, each of which is unsubstituted or mono-, di-, tri- or tetrasubstituted by R4, R4 denotes OH, NH2, NHA or NAA', A, A' each, independently of one another, denote unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F and/or chlorine, Het denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A, Hal denotes F, Cl, Br or I, n denotes 0, 1, 2 or 3; and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as de- scribed in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use can also be made here of variants known per se which are not mentioned here in greater detail. The starting compounds of the formulae la and II are generally known. If they are novel, however, they can be prepared by methods known per se. Compounds of the formula I in which B denotes NHCONH(CH2)nR3 can preferably be obtained by reacting a compound of the formula la with a coupling reagent selected from the group a) isoproylidene chloroformate, b) p-nitrophenyl chloroformate, c) diphosgene, d) triphosgene, and a compound of the formula II. The reaction is preferably carried out as a one-pot reaction. The reaction is generally carried out in an inert solvent. Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -15° and 150°, normally between -5° and 90°, particularly preferably between 20° and 60°C. Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chlo- roform or dichloromethane; alcohols, such as methanol, ethanol, isopropa- nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitrites, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon di- sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com- pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace- tate, or mixtures of the said solvents. Particular preference is given to THF, dichloromethane and/or DMF. The reaction is generally carried out in the presence of an acid-binding agent, preferably an organic base, such as DIPEA, triethylamine, di- methylaniline, pyridine or quinoline. The addition of an alkali or alkaline-earth metal hydroxide, carbonate or bi- carbonate or of another salt of a weak acid of the alkali or alkaline-earth metals, preferably of potassium, sodium, calcium or caesium, may also be favourable. Compounds of the formula I in which B denotes NHCOCONH(CH2)nR3 or NHCOCOO(CH2)nR3 can preferably be obtained by reacting a compound of the formula la with an alkyl chloroformyl formate, subsequently hydrolysing the alkyl oxalaminate, and reacting the resultant oxalamic acid with a compound of the formula II. An activated ester is advantageously formed in situ here, for example through addition of HOBt (hydroxybenzotriazole) or N-hydroxysuccinimide. Radicals of this type for activation of the carboxyl group in typical acylation reactions are described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart;). The reaction is carried out in the presence of a carbodiimide, such as, for example, EDCI (N-ethyl-N,N'-(dimethylaminopropyl)carbodiimide) or dicyclohexylcarbodiimide, an organic base, such as, for example, N- methylmorpholine, and in an inert solvent as indicated above. Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -15° and 150°, normally between -5° and 90°, particularly preferably between 20° and 60°C. Compounds of the formula I can furthermore be obtained by acylating or sulfonylating compounds of the formula la. This is carried out under standard conditions. The reaction is generally carried out in an inert solvent. Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -15° and 150°, normally between -5° and 90°, particularly preferably between 20° and 60°C. Suitable inert solvents are those mentioned above. The reaction is generally carried out in the presence of an acid-binding agent, preferably an organic base, such as DIPEA, triethylamine, dimethyl- aniline, pyridine or quinoline. The addition of an alkali or alkaline-earth metal hydroxide, carbonate or bicarbonate or of another salt of a weak acid of the alkali or alkaline-earth metals, preferably of potassium, sodium, calcium or caesium, may also be favourable. Pharmaceutical salts and other forms The said compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also encompasses the use of these compounds in the form of their pharmaceutically accept- able salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are for the most part prepared by conventional methods. If the compound of the formula I contains a car- boxyl group, one of its suitable salts can be formed by reacting the com- pound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline-earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methyl- glutamine. The aluminium salts of the compounds of the formula I are like- wise included. In the case of certain compounds of the formula I, acid- addition salts can be formed by treating these compounds with pharma- ceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoro- acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascor- bate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula I include the following: acetate, adi- pate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, diglu- conate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethane- sulfonate, fumarate, galacterate (from mucic acid), galacturonate, gluco- heptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydro- bromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso- butyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphos- phate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmo- ate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction. Furthermore, the base salts of the compounds according to the invention include aluminium, ammonium, calcium, copper, iron(lll), iron(ll), lithium, magnesium, nnanganese(lll), manganese(ll), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above-men- tioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline-earth metal salts calcium and magnesium. Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion ex- changer resins, for example arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino- ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpipe- ridine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, pipera- zine, piperidine, polyamine resins, procaine, purines, theobromine, tri- ethanolamine, triethylamine, trimethylamine, tripropylamine and tris- (hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction. Compounds of the present invention which contain basic nitrogen-contain- ing groups can be quaternised using agents such as (C1-C4)alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(C1-C4)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C10-C18)alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl(C1-C4)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-solu- ble compounds according to the invention can be prepared using such salts. The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisucci- nate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, me- glumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stea- rate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and trometh- amine, but this is not intended to represent a restriction. The acid-addition salts of basic compounds of the formula I are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts other- wise correspond to the respective free base forms thereof. As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula I are formed with metals or amines, such as alkali metals and alkaline-earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, di- ethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine. The base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conven- tional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional man- ner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solu- bility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof. If a compound according to the invention contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, di- phosphate, disodium and trihydrochloride, but this is not intended to repre- sent a restriction. With regard to that stated above, it can be seen that the expression "phar- maceutically acceptable salt" in the present connection is taken to mean an active ingredient which comprises a compound of the formula I in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body. The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, sol- vates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants. Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, prefer- ably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a com- pound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient. Furthermore, pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art. Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublin- gual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s). Pharmaceutical formulations adapted for oral administration can be ad- ministered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions. Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present. Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, cal- cium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medica- ment after the capsule has been taken. In addition, if desired or necessary, suitable binders, lubricants and disin- tegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disinteg- rant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl- pyrrolidone, a dissolution retardant, such as, for example, paraffin, an ab- sorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tabletting machine, giving lumps of non-uniform shape, which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units. Oral liquids, such as, for example, solution, syrups and elixirs, can be pre- pared in the form of dosage units so that a given quantity comprises a pre- specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be for- mulated by dispersion of the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added. The dosage unit formulations for oral administration can, if desired, be en- capsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like. The compounds of the formula I and salts, solvates and physiologically functional derivatives thereof can also be administered in the form of lipo- some delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines. The compounds of the formula I and the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal anti- bodies as individual carriers to which the compound molecules are cou- pled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidophenol, polyhydroxy- ethylaspartamidophenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-capro- lactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihy- droxypyrans, polycyanoacrylates and crosslinked or amphipathic block co- polymers of hydrogels. Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986). Pharmaceutical compounds adapted for topical administration can be for- mulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as topical ointment or cream. In the case of formulation to give an ointment, the active ingredient can be employed either with a paraffinic or a water-miscible cream base. Alternatively, the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base. Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or suspended in a suitable carrier, in particular an aqueous solvent. Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes. Pharmaceutical formulations adapted for rectal administration can be ad- ministered in the form of suppositories or enemas. Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil. Pharmaceutical formulations adapted for administration by inhalation en- compass finely particulate dusts or mists, which can be generated by vari- ous types of pressurised dispensers with aerosols, nebulisers or insuffla- tors. Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations. Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxi- dants, buffers, bacteriostatics and solutes, by means of which the formula- tion is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise sus- pension media and thickeners. The formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, imme- diately before use is necessary. Injection solutions and suspensions pre- pared in accordance with the recipe can be prepared from sterile powders, granules and tablets. It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, for- mulations which are suitable for oral administration may comprise flavours. A therapeutically effective amount of a compound of the formula I depends on a number of factors, including, for example, the age and weight of the animal, the precise condition that requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimate- ly determined by the treating doctor or vet. However, an effective amount of a compound according to the invention for the treatment of neoplastic growth, for example colon or breast carcinoma, is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the frac- tion of the effective amount of the compound according to the invention per se. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above. The invention furthermore relates to medicaments comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, sol- vates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient. The invention also relates to a set (kit) consisting of separate packs of (a) an effective amount of a compound of the formula I and/or pharma- ceutically usable derivatives, solvates and stereoisomers thereof, in- cluding mixtures thereof in all ratios, and (b) an effective amount of a further medicament active ingredient. The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate am- poules, each containing an effective amount of a compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient in dis- solved or lyophilised form. USE The present compounds are suitable as pharmaceutical active ingredients for mammals, especially for humans, in the treatment of tyrosine kinase- induced diseases. These diseases include the proliferation of tumour cells, pathological neovascularisation (or angiogenesis) which promotes the growth of solid tumours, ocular neovascularisation (diabetic retinopathy, age-induced macular degeneration and the like) and inflammation (psoria- sis, rheumatoid arthritis and the like). The present invention encompasses the use of the compounds of the for- mula I and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of cancer. Preferred carcinomas for the treatment originate from the group cerebral carcinoma, urogenital tract carcinoma, carcinoma of the lymphatic system, stomach carcinoma, laryngeal carcinoma and lung carcinoma. A further group of preferred forms of cancer are monocytic leukaemia, lung adeno- carcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma. Also encompassed is the use of the compounds according to Claim 1 ac- cording to the invention and/or physiologically acceptable salts and sol- vates thereof for the preparation of a medicament for the treatment or pre- vention of a disease in which angiogenesis is implicated. Such a disease in which angiogenesis is implicated is an ocular disease, such as retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and the like. The use of compounds of the formula I and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of inflammatory diseases also falls within the scope of the present invention. Examples of such inflammatory diseases include rheumatoid arthritis, psoriasis, contact dermatitis, delayed hyper- sensitivity reaction and the like. Also encompassed is the use of the compounds of the formula I and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of a tyrosine kinase-induced disease or a tyrosine kinase-induced condition in a mammal, in which to this method a therapeutically effective amount of a compound according to the invention is administered to a sick mammal in need of such treatment. The therapeutic amount varies according to the specific disease and can be determined by the person skilled in the art without undue effort. The present invention also encompasses the use compounds of the for- mula I and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of retinal vas- cularisation. Methods for the treatment or prevention of ocular diseases, such as dia- betic retinopathy and age-induced macular degeneration, are likewise part of the invention. The use for the treatment or prevention of inflammatory diseases, such as rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reaction, as well as the treatment or prevention of bone pathologies from the group osteosarcoma, osteoarthritis and rickets, likewise falls within the scope of the present invention. The expression "tyrosine kinase-induced diseases or conditions" refers to pathological conditions that depend on the activity of one or more tyrosine kinases. Tyrosine kinases either directly or indirectly participate in the sig- nal transduction pathways of a variety of cellular activities, including prolif- eration, adhesion and migration and differentiation. Diseases associated with tyrosine kinase activity include proliferation of tumour cells, pathologi- cal neovascularisation that promotes the growth of solid tumours, ocular neovascularisation (diabetic retinopathy, age-induced macular degenera- tion and the like) and inflammation (psoriasis, rheumatoid arthritis and the like). The compounds of the formula I can be administered to patients for the treatment of cancer, in particular fast-growing tumours. The invention thus relates to the use of compounds of the formula I, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role. Preference is given here to Met kinase. Preference is given to the use of compounds of the formula I, and pharma- ceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of tyrosine kinases by the compounds accord- ing to Claim 1. Particular preference is given to the use for the preparation of a medica- ment for the treatment of diseases which are influenced by inhibition of Met kinase by the compounds according to Claim 1. Especial preference is given to the use for the treatment of a disease where the disease is a solid tumour. The solid tumour is preferably selected from the group of tumours of the lung, squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach and/or the larynx. The solid tumour is furthermore preferably selected from the group lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblas- tomas, colon carcinoma and breast carcinoma. Preference is furthermore given to the use for the treatment of a tumour of the blood and immune system, preferably for the treatment of a tumour selected from the group of acute myeloid leukaemia, chronic myeloid leu- kaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia. The disclosed compounds of the formula I can be administered in combi- nation with other known therapeutic agents, including anticancer agents. As used here, the term "anticancer agent" relates to any agent which is administered to a patient with cancer for the purposes of treating the can- cer. The anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti- tumour agents: (i) antiproliferative/antineoplastic/DNA-damaging agents and com- binations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chloroambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines, such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids, like vincristine, vinblastine, vindesine and vino- relbine, and taxoids, like taxol and taxotere); topoisomerase inhibitors (for example epipodophyllotoxins, like etoposide and teniposide, amsacrine, topotecan, irinotecan and camptothecin) and cell-differentiating agents (for example all-trans-retinoic acid, 13-cis-retinoic acid and fenretinide); (ii) cytostatic agents, such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor downregulatoirs (for example fulvestrant), antiandrogens (for example bi- calutamide, flutamide, nilutamide and cyproterone acetate), LHRH antago- nists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progesterones (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibi- tors of 5a-reductase, such as finasteride; (iii) agents which inhibit cancer cell invasion (for example metallo- proteinase inhibitors, like marimastat, and inhibitors of urokinase plasmi- nogen activator receptor function); (iv) inhibitors of growth factor function, for example such inhibitors in- clude growth factor antibodies, growth factor receptor antibodies (for ex- ample the anti-erbb2 antibody trastuzumab [Herceptin™] and the anti-erbbl antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors, such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6- (3- morpholinopropoxy) quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynyl- phenyl)-6,7-bis (2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)- quinazolin-4-amine (Cl 1033)), for example inhibitors of the platelet- derived growth factor family and for example inhibitors of the hepatocyte growth factor family; (v)antiangiogenic agents, such as those which inhibit the effects of vascu- lar endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [Avastin™], compounds such as those disclosed in published international patent applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibi- tors of integrin v3 function and angiostatin); (vi) vessel-damaging agents, such as combretastatin A4 and com- pounds disclosed in international patent applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-Ras antisense; (viii) gene therapy approaches, including, for example, approaches for replacement of aberrant genes, such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches, such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme, and approaches for increasing patient tolerance to chemotherapy or radiotherapy, such as multi-drug resistance gene ther- apy; and (ix) immunotherapy approaches, including, for example, ex-vivo. and in-vivo approaches for increasing the immunogenicity of patient tumour cells, such as transfection with cytokines, such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches for decreasing T-cell anergy, approaches using transfected immune cells, such as cytokine-transfected dendritic cells, approaches using cytokine- transfected tumour cell lines, and approaches using anti-idiotypic anti- bodies. The medicaments from Table 1 below are preferably, but not exclusively, combined with the compounds of the formula I. A combined treatment of this type can be achieved with the aid of simulta- neous, consecutive or separate dispensing of the individual components of the treatment. Combination products of this type employ the compounds according to the invention. ASSAYS The compounds of the formula I described in the examples were tested by the assays described below and were found to have kinase inhibitory activity. Other assays are known from the literature and could readily be performed by the person skilled in the art (see, for example, Dhanabal et al., Cancer Res. 59:189-197; Xin et al., J. Biol. Chem. 274:9116-9121; Sheu et al., Anticancer Res. 18:4435-4441; Ausprunk et al., Dev. Biol. 38:237-248; Gimbrone et al., J. Natl. Cancer Inst. 52:413-427; Nicosia et al., In Vitro 18:538- 549). Measurement of Met kinase activity According to the manufacturer's data (Met, active, upstate, catalogue No. 14-526), Met kinase is expressed for the purposes of protein production in insect cells (Sf21; S. frugiperda) and subsequent affinity-chromatographic purification as "N-temninal 6His-tagged" recombinant human protein in a baculovirus expression vector. The kinase activity can be measured using various available measurement systems. In the scintillation proximity method (Sorg et al., J. of Biomolecu- lar Screening, 2002, 7, 11-19), the flashplate method or the filter binding test, the radioactive phosphorylation of a protein or peptide as substrate is measured using radioactively labelled ATP (32P-ATP, 33P-ATP). In the case of the presence of an inhibitory compound, a reduced radioactive signal, or none at all, can be detected. Furthermore, homogeneous time- resolved fluorescence resonance energy transfer (HTR-FRET) and fluoroescence polarisation (FP) technologies can be used as assay meth- ods (Sills et al., J. of Biomolecular Screening, 2002, 191-214). Other non-radioactive ELISA assay methods use specific phospho-anti- bodies (phospho-ABs). The phospho-antibody only binds the phosphor- ylated substrate. This binding can be detected by chemiluminescence using a second peroxidase-conjugated antibody (Ross et al., 2002, Bio- chem. J.). Flashplate method (Met kinase) The test plates used are 96-well FlashplateR microtitre plates from Perkin Elmer (Cat. No. SMP200). The components of the kinase reaction de- scribed below are pipetted into the assay plate. The Met kinase and the substrate poly Ala-Glu-Lys-Tyr, (pAGLT, 6:2:5:1), are incubated for 3 hrs at room temperature with radioactively labelled 33P-ATP in the presence and absence of test substances in a total volume of 100 l. The reaction is terminated using 150 l of a 60 mM EDTA solution. After incubation for a further 30 min at room temperature, the supernatants are filtered off with suction, and the wells are washed three times with 200 l of 0.9% NaCI solution each time. The measurement of the bound radioactivity is carried out by means of a scintillation measuring instrument (Topcount NXT, Perkin-Elmer). The full value used is the inhibitor-free kinase reaction. This should be ap- proximately in the range 6000-9000 cpm. The pharmacological zero value used is staurosporin in a final concentration of 0.1 mM. The inhibitory values (IC50) are determined using the RS1_MTS program. Kinase reaction conditions per well: 30 l of assay buffer 10 l of substance to be tested in assay buffer with 10% of DMSO 10 l of ATP (final concentration 1 M cold, 0.35 Ci of 33P-ATP) 50 l of Met kinase/substrate mixture in assay buffer; (10 ng of enzyme/well, 50 ng of pAGLT/well) Solutions used: - Assay buffer: 50 mM HEPES 3 mM magnesium chloride 3 M sodium orthovanadate 3 mM manganese(ll) chloride 1 mM dithiothreitol (DTT) pH = 7.5 (to be set using sodium hydroxide) - Stop solution: 60 mM Titriplex III (EDTA) - 33P-ATP: Perkin-Elmer; - Met kinase: Upstate, Cat. No. 14-526, Stock 1 g/10 ul; spec, activity 954 U/mg; Poly-Ala-Glu-Lys-Tyr, 6:2:5:1: Sigma Cat. No. P1152 Above and below, all temperatures are indicated in °C. In the following ex- amples, "conventional work-up" means: water is added if necessary, the pH is adjusted, if necessary, to values between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl ace- tate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, and the residue is purified by chromatography on silica gel and/or by crystallisation. Rf values on silica gel; eluent: ethyl acetate/methanol 9:1. Mass spectrometry (MS): El (electron impact ionisation) M+ FAB (fast atom bombardment) (M+H)+ ESI (electrospray ionisation) (M+H)+ APCI-MS (atmospheric pressure chemical ionisation - mass spectrometry) (M+H)+. Retention time RT [min]: determination by HPLC Column: ChromolithPerformance RP-18e (Merck KGaA, Cat. 1.02129.0001) Eluents: Eluent A: 0.1 M aqueous NaH2PO4 Eluent B: acetonitrile + 10% of water Flow rate: 4 ml/min Gradient: 0 min 1 % of B 1 min 1 % of B 7 min 99% of B 8 min 99% of B Wavelength (detection): 220 nm Example 1 The preparation of 1-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4-thiadiazin-3-yl- methyl]phenyl}-3-(1-methylpyrrolidin-3-ylmethyl)urea ("A1") is carried out analogously to the following scheme a) If the requisite haloacetophenones are not commercially available, they can be prepared analogously to the following synthetic procedure: 5.57 g of 3,4-dimethoxyacetophenone are dissolved in 60 ml of diethyl ether and 30 ml of 1,4-dioxane in a 250 ml three-necked flask provided with magnetic stirrer, condenser, thermometer, dropping funnel with pres- sure equalisation and drying tube, and 1.54 ml of bromine are added dropwise with stirring at RT, during which a precipitate forms after only a short time. The mixture is stirred at RT for a further 1 h, during which the precipitate re-dissolves, the temperature is raised by about 3°C, and a pale-yellow, clear solution forms. This is poured onto ice, stirred well, and the precipitate formed between the phases is filtered off with suction. It is washed with water and then with a little MTB ether and dried (=K1). The mother liquor is extracted with MTB ether, dried, filtered and evaporated to dryness. The residue is triturated with a little MTB ether, filtered off with suction and dried (=K2). K1 and K2 are combined, giving 2'-bromo-4- chloroacetophenone, m.p. 91-92°; yield: 5.88 g (76%). b) 8.09 ml of hydrazinium hydroxide are slowly added dropwise to a solution of 25.65 g of potassium O-ethyldithiocarbonate in 24 ml of water with stir- ring, and the mixture is stirred at room temperature for a further 6 h. The mixture is left to stand at room temperature for 16 h, then 12 ml of water are added, and the mixture is extracted with ether. The combined ether phases are dried, filtered and evaporated to dryness, giving 16.4 g of ethyl hydrazinecarbothionate. c) 5.17 g of ethyl hydrazinecarbothionate (43 mmol) are added to a solution of 10.04 g of 2'-bromo-4-chloroacetophenone (43 mmol) in 40 ml of aceto- nitrile, and the mixture is stirred at RT for 3 h, during which a precipitate forms little by little. The reaction mixture is filtered with suction, washed with a little acetonitrile and then with ether and dried, giving 6.59 g (68%) of 5-(4-chlorophenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one. d) 4.19 g of 3-nitrobenzyl bromide and 9.95 g of potassium carbonate are added to a solution of 4.00 g of 5-(4-chlorophenyl)-3,6-dihydro-1,3,4- thiadiazin-2-one in 80 ml of acetonitrile, and the mixture is stirred at 80° for a further 2 h. The mixture is poured into water, extracted 2x with diethyl ether, dried, filtered and evaporated to dryness. A little diethyl ether is added to the residue, which is crystallised and dried in a vacuum drying cabinet at 50°C, giving 5.5 g (86%) of 5-(4-chlorophenyl)-3-(3-nitrobenzyl)- 3,6-dihydro-1,3,4-thiadiazin-2-one. e) 5.47 g of 5-(4-chlorophenyl)-3-(3-nitrobenzyl)-3,6-dihydro-1,3,4-thiadiazin- 2-one is dissolved in 100 ml of THF, and 1.3 g of Raney nickel is subse- quently added. Hydrogen is subsequently passed in until starting material is no longer detectable. For work-up, the catalyst is filtered off, washed with THF, and the filtrate is evaporated to dryness and recrystallised from dichloromethane/diethyl ether, giving 4.6 g (94%) of 3-(3-aminobenzyl)-5- (4-chlorophenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one. f) 200 mg (0.603 mmol) of 3-(3-aminobenzyl)-5-(4-chlorophenyl)-3,6-dihydro- 1,3,4-thiadiazin-2-one, 121 mg (0.603 mmol) of 4-nitrophenyl chloro- formate and 50 ul of pyridine (0.6 mmol) are dissolved in 2 ml of dichloro- methane in a multistirrer vessel and subsequently stirred at room tempera- ture for 40 min. A solution of 104 mg (0.904 mmol) of C-(1-methylpyrroli- din-3-yl)methylamine and 230 l of diisopropylethylamine in 1 ml of di- chloromethane is subsequently added, and the reaction mixture is stirred at room temperature for 16 h. For work-up, the mixture is diluted with 20 ml of dichloromethane, the org. phase is washed with 10 ml of 1 N NaOH, dried over sodium sulfate and evaporated to dryness in a rotary evaporator. The purification is carried out by chromatography (about 10 g of silica gel Si 60, 25 - 40 m, gradient (dichloromethane/methanol):30 min 10 - 60% of MeOH /15 ml/min) The product fractions are evaporated to dryness and crystallised from dichloromethane/diethyl ether. Yield: 67 mg (24%) of ("A1"), m.p. 105-107°; RT4.45 min; 1H NMR (250 MHz, DMSO-d6)  8.453 (S, 1H), 7.859 (D, 2H), 7.550 (D, 2H), 7.406 (S, 1H), 7.308 (D, 1H), 7.180 (T, 1H), 6.872 (D, 1H), 6.203 (T, 1H), 4.976 (S, 2H), 4.331 (S, 2H), 3.053 (T, 2H), 2.493 (M, 2H), 2.422 (M, 2H), 2.238 (M, 2H), 2.238 (S, 3H), 1.862 (M, 1H), 1.408 (M, 1H). The following compounds are obtained analogously Example 2 The preparation of N-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4-thiadiazin-3- ylmethyl]phenyl}-N'-(2-dimethylaminoethyl)oxalamide ("A7") is carried out analogously to the following scheme 2.1 400 mg (1.205 mmol) of 3-(3-aminobenzyl)-5-(4-chlorophenyl)-3,6-dihydro- 1,3,4-thiadiazin-2-one (from Example 1e) and 126 l (1.567 mmol) of pyridine are dissolved in 5 ml of dichloromethane in an 8 ml multistirrer vessel, and 147 l (1.325 mmol) of ethyl chloroformylformate are subse- quently added at RT. When the addition is complete, the mixture is stirred for a further 15 min. For work-up, the reaction mixture is diluted with 20 ml of dichloromethane and subsequently washed with 10 ml of 1 N aqueous HCI, dried over Na2SO4 and evaporated to dryness in a rotary evaporator. The residue is crystallised from methanol/diethyl ether. Yield 445 mg (85%) of ethyl N-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4-thiadiazin-3- ylmethyl]phenyl}oxalaminate ("A9"), RT 5.68. 2.2 400 mg (0.926 mmol) of ethyl N-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4- thiadiazin-3-ylmethyl]phenyl}oxalaminate are dissolved in 4 ml of methanol, and 47 mg (1.111 mmol) of LiOH x H2O are subsequently added. The reaction mixture is stirred at RT for 30 min. For work-up, the reaction mixture is diluted with 30 ml of dichloromethane and subsequently washed with 10 ml of 1 N aqueous HCI. During this operation, the product precipitates out in a separating funnel. The precipitate is filtered off with suction, triturated with diethyl ether and dried at 50°C in a drying cabinet. Yield 319 mg (85%) of N-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4-thiadiazin- 3-ylmethyl]phenyl}oxalamic acid ("A8"), RT 4.27. 2.3 120 mg (0.297 mmol) of N-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4-thia- diazin-3-ylmethyl]phenyl}oxalamic acid, 27 mg (0.3 mmol) of N,N-dimethyl- ethanediamine, 115 mg of EDCI (0.6 mmol), 41 mg (0.3 mmol) of hydroxy- benzotriazole and 61 mg (0.6 mmol) of N-methylmorpholine are dissolved in 1 ml of dimethylformamide in an 8 ml multistirrer vessel and stirred overnight at room temperature. The reaction mixture is purified by RP- HPLC (acetonitrile/H2O / 0.1% of TFA: gradient 1-60% of B). Yield: 45 mg (32%) of N-{3-[5-(4-chlorophenyl)-2-oxo-6H-1,3,4-thiadiazin-3-ylmethyl]- phenyl}-N'-(2-dimethylaminoethyl)oxalamide (trifluoroacetate) ("A7"). with methylsulfonyl chloride under standard conditions gives compound Example 3 Compound "A14" is obtained analogously Pharmacological data Met kinase inhibition IC50: 10nM-1 M=A 1 M-10M = B > 10 mM = C The following examples relate to medicaments: Example A: Injection vials A solution of 100 g of an active ingredient of the formula I and 5 g of diso- dium hydrogenphosphate in 3 I of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient. Example B: Suppositories A mixture of 20 g of an active ingredient of the formula I with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient. Example C: Solution A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH2PO4 • 2 H2O, 28.48 g of Na2HPO4 • 12 H2O and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 I and sterilised by irradiation. This solution can be used in the form of eye drops. Example D: Ointment 500 mg of an active ingredient of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions. Example E: Tablets A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed in a conventional manner to give tablets in such a way that each tablet contains 10 mg of active ingredient. Example F: Dragees Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, traga- canth and dye. Example G: Capsules 2 kg of active ingredient of the formula I are introduced into hard gelatine capsules in a conventional manner in such a way that each capsule con- tains 20 mg of the active ingredient. Example H: Ampoules A solution of 1 kg of active ingredient of the formula I in 60 I of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient. Patent Claims 1. Compounds of the formula I in which R1 denotes H, A, Hal, OH, OA, SH, SA, SOA, SO2A, NO2, NH2, NHA, NAA', SO2NH2, SO2NHA, SO2NAA', CONH2, CONHA, CONAA', NACOA', NASO2A', COOH, COOA or CN, R2 denotes H, A, Hal, SO2NH2, SO2NHA, SO2NAA', CONH2, CONHA, CONAA', NACOA', NASO2A', COOH, COOA or CN, R1 and R2 together also denote methylenedioxy, B is absent, denotes NHCOCONH(CH2)nR3, NHCOCONA(CH2)nR3, NHCOCOO(CH2)nR3, OCONH(CH2)nR3, OCONA(CH2)nR3, NHCONH(CH2)nR3, NACONH(CH2)nR3, N(CH2)nR3, CONH(CH2)nR3, SO2NH(CH2)nR3, SO2NA(CH2)nR3, NHSO2(CH2)nR3 or NASO2(CH2)nR3, Q is absent or denotes alkylene having 1-4 C atoms, R3 denotes R1, Het or alkyl having 1-6 C atoms or cycloalkyl having 3-8 C atoms, each of which is unsubstituted or mono-, di-, tri- ortetra- substituted by R4, R4 denotes A, Hal, OH, OA, SH, SA, SOA, SO2A, NO2, NH2, NHA, NAA', SO2NH2, SO2NHA, SO2NAA', CONH2, CONHA, CONAA', NACOA', NASO2A', COOH, COOA or CN, Het denotes a mono- or bicyclic saturated heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by R4, CHO, COA, =S, =NH, =NA and/or =O (carbonyl oxygen), A, A' each, independently of one another, denote unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms may be replaced by F, Cl and/or Br, cycloalkyl having 3-8 C atoms or cycloalkylalkylene having 4-10 C atoms, Hal denotes F, Cl, Br or I, n denotes 0, 1, 2 or 3, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 2. Compounds according to Claim 1 in which R1 denotes Hal, OH or CN, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 3. Compounds according to Claim 1 or 2 in which R2 denotes H or Hal, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 4. Compounds according to one or more of Claims 1-3 in which B denotes NHCOCONH(CH2)nR3, NHCOCOO(CH2)nR3, NHCONH(CH2)nR3 or NHSO2(CH2)nR3, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 5. Compounds according to one or more of Claims 1-4 in which Q denotes CH2, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 6. Compounds according to one or more of Claims 1-5 in which R3 denotes H, Het or alkyl having 1-6 C atoms or cycloalkyl having 3-8 C atoms, each of which is unsubstituted or mono-, di-, tri- or tetrasubstituted by R4, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 7. Compounds according to one or more of Claims 1-6 in which R4 denotes OH, NH2, NHA or NAA', and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 8. Compounds according to one or more of Claims 1-7 in which A, A' each, independently of one another, denote unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F and/or chlorine, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 9. Compounds according to one or more of Claims 1-8 in which Het denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 10. Compounds according to one or more of Claims 1 -9 in which R1 denotes Hal, OH or CN, R2 denotes H or Hal, B denotes NHCOCONH(CH2)nR3, NHCOCOO(CH2)nR3, NHCONH(CH2)nR3 or NHSO2(CH2)nR3, Q denotes CH2, R3 denotes H, Het or alkyl having 1-6 C atoms or cycloalkyl having 3-8 C atoms, each of which is unsubstituted or mono-, di-, tri- or tetra- substituted by R4, R4 denotes OH, NH2, NHA or NAA', A, A' each, independently of one another, denote unbranched or branched alkyl having 1-6 C atoms, in which 1-5 H atoms may be replaced by F and/or chlorine, Het denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A, Hal denotes F, Cl, Br or I, n denotes 0, 1, 2 or 3, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 11. Compounds according to Claim 1, selected from the group and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 12. Process for the preparation of compounds of the formula I according to Claims 1-11 and pharmaceutically usable derivatives, salts, sol- vates, tautomers and stereoisomers thereof, characterised in that a) a compound of the formula la in which B denotes NH2, and R1, R2 and Q have the meanings indicated in Claim 1, is converted into a compound of the formula I in which B denotes NHCONH(CH2)nR3, by reacting a compound of the formula la with a coupling reagent selected from the group a) isoproylidene chloroformate, b) p-nitrophenyl chloroformate, c) diphosgene, d) triphosgene, and a compound of the formula II H2N(CH2)nR3 II in which n and R3 have the meanings indicated in Claim 1, or b) a compound of the formula la is acylated or sulfonylated and/or a base or acid of the formula I is converted into one of its salts. 13. Medicaments comprising at least one compound of the formula I ac- cording to Claim 1-11 and/or pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mix- tures thereof in all ratios, and optionally excipients and/or adjuvants. 14. Use of compounds according to Claim 1 -11 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role. 15. Use according to Claim 14 of compounds according to Claim 1-11, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of tyrosine kinases by the com- pounds according to Claim 1-11. 16. Use according to Claim 14 for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of Met kinase by the compounds according to Claim 1-11. 17. Use according to Claim 15 or 16, where the disease to be treated is a solid tumour. 18. Use according to Claim 17, where the solid tumour originates from the group of tumours of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the uro- genital tract, the lymphatic system, the stomach, the larynx and/or the lung. 19. Use according to Claim 17, where the solid tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carci- noma. 20. Use according to Claim 18, where the solid tumour originates from the group of lung adenocarcinoma, small-cell lung carcinomas, pan- creatic cancer, glioblastomas, colon carcinoma and breast carci- noma. 21. Use according to Claim 15 or 16, where the disease to be treated is a tumour of the blood and immune system. 22. Use according to Claim 21, where the tumour originates from the group of acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia. 23. Medicaments comprising at least one compound of the formula I ac- cording to one or more of Claims 1 to 11, and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient. 24. Set (kit) consisting of separate packs of (a) an effective amount of a compound of the formula I according to one or more of Claims 1 to 11, and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mix- tures thereof in all ratios, and (b) an effective amount of a further medicament active ingredient. Compounds of the formula I, in which R1, R2, Q and B have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular of Met Kinase and can be employed, inter alia, for treatment of tumours.

Documents:

02435-kolnp-2008-abstract.pdf

02435-kolnp-2008-claims.pdf

02435-kolnp-2008-correspondence others.pdf

02435-kolnp-2008-description complete.pdf

02435-kolnp-2008-form 1.pdf

02435-kolnp-2008-form 2.pdf

02435-kolnp-2008-form 3.pdf

02435-kolnp-2008-form 5.pdf

02435-kolnp-2008-gpa.pdf

02435-kolnp-2008-international publication.pdf

02435-kolnp-2008-international search report.pdf

02435-kolnp-2008-pct priority document notification.pdf

02435-kolnp-2008-pct request form.pdf

02435-kolnp-2008-translated copy of priority document.pdf

2435-KOLNP-2008-(12-04-2013)-ABSTRACT.pdf

2435-KOLNP-2008-(12-04-2013)-ANNEXURE TO FORM 3.pdf

2435-KOLNP-2008-(12-04-2013)-CLAIMS.pdf

2435-KOLNP-2008-(12-04-2013)-CORRESPONDENCE.pdf

2435-KOLNP-2008-(12-04-2013)-OTHERS.pdf

2435-KOLNP-2008-(12-04-2013)-PETITION UNDER RULE 137.pdf

2435-KOLNP-2008-(21-02-2014)-ABSTRACT.pdf

2435-KOLNP-2008-(21-02-2014)-CLAIMS.pdf

2435-KOLNP-2008-(21-02-2014)-CORRESPONDENCE.pdf

2435-KOLNP-2008-(25-02-2014)-AMENDED CLAIMS.pdf

2435-KOLNP-2008-CORRESPONDENCE OTHERS 1.1.pdf

2435-KOLNP-2008-FORM 18.pdf

2435-KOLNP-2008-OTHERS.pdf

abstract-02435-kolnp-2008.jpg